{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:59:59Z","timestamp":1785473999236,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01549-0","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:41:01Z","timestamp":1785422461000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oligoprogression in Advanced Gastric and Gastroesophageal Junction Cancer: Integrating Local Therapy, Systemic Treatment Continuation, and Biomarker Reassessment"],"prefix":"10.1007","volume":"57","author":[{"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"1549_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"1549_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"1549_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Yanez P, et al. The KEYNOTE-811 trial of pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma. Nature. 2021;600:727\u201330.","journal-title":"Nature"},{"key":"1549_CR4","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368.","journal-title":"Lancet"},{"key":"1549_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2023.02.015","volume":"185","author":"TE Kroese","year":"2023","unstructured":"Kroese TE, van Laarhoven HWM, Schoppmann SF, et al. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a Delphi consensus study in Europe. Eur J Cancer. 2023;185:28\u201339.","journal-title":"Eur J Cancer"},{"key":"1549_CR6","doi-asserted-by":"publisher","first-page":"114062","DOI":"10.1016\/j.ejca.2024.114062","volume":"204","author":"TE Kroese","year":"2024","unstructured":"Kroese TE, Bronzwaer SFC, van Rossum PSN, et al. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer. 2024;204:114062.","journal-title":"Eur J Cancer"},{"key":"1549_CR7","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: an ESTRO and EORTC consensus recommendation. Lancet Oncol. 2020;21:e18\u201328.","journal-title":"Lancet Oncol"},{"key":"1549_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR, Oligometastases. J Clin Oncol. 1995;13:8\u201310.","journal-title":"J Clin Oncol"},{"key":"1549_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejca.2022.02.018","volume":"166","author":"TE Kroese","year":"2022","unstructured":"Kroese TE, van Laarhoven HWM, Nilsson M, et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: a systematic review and meta-analysis. Eur J Cancer. 2022;166:254\u201369.","journal-title":"Eur J Cancer"},{"key":"1549_CR10","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3:1237\u201344.","journal-title":"JAMA Oncol"},{"key":"1549_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309\u201318.","journal-title":"Lancet Oncol"},{"key":"1549_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/ags3.12733","volume":"8","author":"K Hara","year":"2024","unstructured":"Hara K, Cho H, Onodera A, et al. Long-term treatment outcomes in gastric cancer with oligometastasis. Ann Gastroenterol Surg. 2024;8:60\u201370.","journal-title":"Ann Gastroenterol Surg"},{"key":"1549_CR13","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jrr\/rrad066","volume":"64","author":"H Yamaguchi","year":"2023","unstructured":"Yamaguchi H, Fukumitsu N, Numajiri H, et al. The Japanese nationwide cohort data of proton beam therapy for liver oligometastasis in esophagogastric cancer patients. J Radiat Res. 2023;64:926\u201332.","journal-title":"J Radiat Res"},{"key":"1549_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3390\/cancers16040797","volume":"16","author":"SJM van Hootegem","year":"2024","unstructured":"van Hootegem SJM, de Pasqual CA, Giacopuzzi S, et al. Outcomes after surgical treatment of oesophagogastric cancer with synchronous liver metastases: a multicentre retrospective cohort study. Cancers (Basel). 2024;16:797.","journal-title":"Cancers (Basel)"},{"key":"1549_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s13691-023-00611-z","volume":"12","author":"Y Seyama","year":"2023","unstructured":"Seyama Y, Yamada T, Suzuki H, et al. Gastric neuroendocrine carcinoma presenting complete durable response by nivolumab treatment for multiple metastases and radiotherapy to oligoprogressive metastasis. Int Cancer Conf J. 2023;12:268\u201373.","journal-title":"Int Cancer Conf J"},{"key":"1549_CR16","doi-asserted-by":"publisher","first-page":"1268199","DOI":"10.3389\/fonc.2023.1268199","volume":"13","author":"L Shao","year":"2023","unstructured":"Shao L, Zhang H, He W, Wu J, Zhu D, Cheng H. Advanced gastric cancer with metachronous intracranial oligometastases without recurrence after multidisciplinary team discussion and comprehensive treatment: a case report. Front Oncol. 2023;13:1268199.","journal-title":"Front Oncol"},{"key":"1549_CR17","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830\u20138.","journal-title":"J Clin Oncol"},{"key":"1549_CR18","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558\u201365.","journal-title":"J Clin Oncol"},{"key":"1549_CR19","first-page":"1","volume":"35","author":"ZR Zhao","year":"2016","unstructured":"Zhao ZR, Yang CP, Lin Y, et al. Molecular heterogeneity of gastric cancer and clinical implications. Chin J Cancer. 2016;35:1.","journal-title":"Chin J Cancer"},{"key":"1549_CR20","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1002\/ijc.30408","volume":"139","author":"F Pietrantonio","year":"2016","unstructured":"Pietrantonio F, Caporale M, Morano F, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research. Int J Cancer. 2016;139:2859\u201364.","journal-title":"Int J Cancer"},{"key":"1549_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","volume":"22","author":"S Seo","year":"2019","unstructured":"Seo S, Ryu MH, Park YS, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2019;22:527\u201335.","journal-title":"Gastric Cancer"},{"key":"1549_CR22","doi-asserted-by":"crossref","unstructured":"Kubota Y, Kawazoe A, Mishima S et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023;8:100762. Corrigendum in: ESMO Open. 2024;9:101541.","DOI":"10.1016\/j.esmoop.2022.100762"},{"key":"1549_CR23","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1186\/s40064-016-3205-2","volume":"5","author":"JY Kim","year":"2016","unstructured":"Kim JY, Ryu MH, Yoo C, et al. Krukenberg tumor from gastric cancer: a retrospective analysis. SpringerPlus. 2016;5:1617.","journal-title":"SpringerPlus"},{"key":"1549_CR24","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.4251\/wjgo.v15.i6.1096","volume":"15","author":"ML Zhou","year":"2023","unstructured":"Zhou ML, Xu RN, Tan C, Zhang Z, Wan JF. Advanced gastric cancer achieving major pathologic regression after chemoimmunotherapy combined with hypofractionated radiotherapy: a case report. World J Gastrointest Oncol. 2023;15:1096\u2013104.","journal-title":"World J Gastrointest Oncol"},{"key":"1549_CR25","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330.","journal-title":"N Engl J Med"},{"key":"1549_CR26","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","volume":"25","author":"SB Maron","year":"2019","unstructured":"Maron SB, Chase LM, Lomnicki S, et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin Cancer Res. 2019;25:7098\u2013112.","journal-title":"Clin Cancer Res"},{"key":"1549_CR27","doi-asserted-by":"publisher","first-page":"100108","DOI":"10.1016\/j.esmogo.2024.100108","volume":"6","author":"Y Narita","year":"2024","unstructured":"Narita Y, Muro K, Takahari D. Practical management of oligometastatic gastric cancer. ESMO Gastrointest Oncol. 2024;6:100108.","journal-title":"ESMO Gastrointest Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01549-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01549-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01549-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:31:20Z","timestamp":1785472280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01549-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01549-0","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"170"}}